Introduction

Respiratory Distress Syndrome (RDS) remains a significant challenge in neonates (babies <28 days old), especially among premature babies. RDS is the fragile respiratory system of newborns, leading to respiratory distress and potentially life-threatening complications.¹ It is characterised by a deficiency in surfactant, a protein in the lungs. 

Amidst the complexities of RDS, surfactant therapy emerges as a beacon of hope, offering a promising avenue for restoring lung function and improving outcomes. 

In this comprehensive exploration, we embark on a journey to unravel the intricacies of RDS, dissect the mechanisms of surfactant therapy, and explore its transformative potential in neonatal care.

Understanding RDS

RDS represents a critical hurdle in the care of premature babies, arising from an imbalance in surfactant production and lung development.¹ Surfactant, a complex mixture of fats and proteins, is crucial in reducing surface tension within the alveoli, preventing collapse during breathing out and facilitating gas exchange.

In premature infants, inadequate surfactant levels result in alveolar collapse, impaired gas exchange, and respiratory distress. Risk factors for RDS include prematurity, maternal diabetes, caesarean delivery, and fatal lung immaturity.¹

How does RDS happen?

The cause of RDS is multifaceted resulting from: surfactant deficiency, immature lungs, and inflammation. 

Premature birth interrupts the normal maturation of the fetal lung, leading to insufficient surfactant production by type II alveolar cells. Without adequate surfactant, the alveoli become unstable, leading to collapse, a mismatch between oxygen intake and blood flow, and low oxygen levels.²

Furthermore, the inflammatory cascade triggered by lung immaturity exacerbates tissue damage, worsening respiratory distress and potentially resulting in long-term complications such as bronchopulmonary dysplasia and neurodevelopmental impairment.

Surfactant therapy

Surfactant therapy represents a cornerstone in managing RDS, aiming to replenish deficient surfactant levels and restore alveolar stability. There are two main types of surfactant: 

Natural surfactants

Derived from animal or human sources, closely mimic the composition and function of endogenous surfactant, offering optimal biocompatibility and efficacy. They undergo rigorous processing to remove components which could trigger the immune system while retaining surfactant activity. 

Synthetic surfactants: (lucinactant or beractant)

These are engineered to replicate the properties of natural surfactants using synthetic lipids and surfactant proteins. While synthetic surfactants offer advantages such as consistency and sterility, they may lack some biological activity and immunomodulatory properties of natural surfactants.^2,3

Effectiveness and benefits of surfactant therapy

The effectiveness of surfactant therapy in RDS management is well-documented, with numerous studies demonstrating its ability to improve oxygenation, reduce the need for mechanical ventilation, and mitigate the risk of complications such as bronchopulmonary dysplasia.^3,4 

Early initiation of surfactant therapy, preferably within the first hour of life or soon after birth, has been associated with improved clinical outcomes and reduced mortality rates in premature infants with RDS. Moreover, surfactant therapy has been shown to improve long-term neurodevelopmental outcomes in preterm infants, highlighting its profound impact on the overall well-being of these vulnerable patients.

Indications and timing of surfactant therapy

The decision to initiate surfactant therapy is based on thorough clinical assessment and evidence-based criteria, including the level of prematurity severity of respiratory distress, and oxygenation status. 

Infants born at less than 30 weeks or with signs of moderate to severe respiratory distress are typically considered candidates for surfactant therapy. Additionally, infants with a history of meconium aspiration syndrome or other respiratory conditions may benefit from surfactant therapy. 

Early administration of surfactant therapy, ideally within the golden hour of life or soon after birth, is crucial to maximising its effectiveness and minimising the risk of adverse outcomes. However, individualised management and close monitoring are essential to tailor therapy to the specific needs of each patient.

Administration techniques and considerations

Surfactant therapy can be administered via various techniques, each with its advantages and considerations. The most common method involves endotracheal tube installation, where surfactant is delivered directly into the infant's lungs via an endotracheal tube. 

Alternatively, minimally invasive techniques such as Less Invasive Surfactant Administration (LISA) or Minimally Invasive Surfactant Therapy (MIST) allow for surfactant administration without the requiring intubation, reducing the risk of complications associated with mechanical ventilation.⁵ 

Dosage, frequency, and mode of delivery are tailored to individual patient characteristics and disease severity, with meticulous attention to safety and efficacy considerations. Vigilant monitoring for adverse effects, such as bradycardia or desaturation, is paramount to ensuring patient safety and optimising treatment outcomes.

Surfactant therapy in special populations

While surfactant therapy is predominantly associated with premature infants, its therapeutic potential extends to diverse patient populations, including term infants with conditions such as meconium aspiration syndrome (MAS) or persistent pulmonary hypertension of the newborn (PPHN). 

Additionally, surfactant therapy may benefit adult populations with conditions such as Acute Respiratory Distress Syndrome (ARDS), where it aims to optimise lung function and improve clinical outcomes.⁴

Future directions and ongoing research

The landscape of surfactant therapy is continuously evolving, with ongoing research focusing on refining existing formulations, exploring novel delivery mechanisms, and investigating adjunctive therapies. 

Targeted approaches, personalised medicine, and advancements in regenerative medicine hold promise for optimising surfactant therapy and improving outcomes for neonates with RDS and related respiratory conditions. 

Additionally, collaborative efforts between researchers, clinicians, and industry stakeholders are essential to translate scientific discoveries into innovative therapies that address the unmet needs of neonatal patients.

Conclusion

Surfactant therapy stands as a beacon of hope in the management of Respiratory Distress Syndrome, offering a lifeline to neonates grappling with the challenges of pulmonary immaturity. 

Through its ability to replenish surfactant levels, restore pulmonary function, and mitigate complications, surfactant therapy represents a transformative advancement in neonatal care. 

As we navigate the evolving landscape of neonatal medicine, let us continue to embrace innovation, collaboration, and evidence-based practice to ensure the best possible outcomes for our tiniest patients.

Summary

In summary, Respiratory Distress Syndrome remains a significant concern in neonatal medicine, particularly among premature infants. Surfactant therapy has revolutionised the management of RDS, offering a targeted approach to address surfactant deficiency and restore lung function. 

By understanding the pathophysiology of RDS, recognising the indications for surfactant therapy, and implementing appropriate administration techniques, healthcare providers can optimise outcomes for neonates battling this challenging condition. 

With ongoing research and collaborative efforts, the future holds promise for further advancements in surfactant therapy, ultimately improving the quality of care and outcomes for neonates worldwide.

FAQs

How is RDS treated with surfactant?

Surfactant therapy is a primary treatment modality for Respiratory Distress Syndrome (RDS). It involves administering exogenous surfactant directly into the lungs of premature infants to alleviate surfactant deficiency and improve lung function.

What drugs are used for surfactant therapy?

Various types of surfactant drugs are used for therapy, including natural surfactants derived from animal or human sources (e.g., porcine-derived or bovine-derived surfactants) and synthetic surfactants (e.g., lucinactant or beractant).

Why does surfactant work for respiratory distress syndrome?

Surfactant works for Respiratory Distress Syndrome by reducing surface tension within the alveoli, preventing collapse during expiration, and facilitating gas exchange. 

In premature infants with RDS, exogenous surfactant supplementation helps restore adequate surfactant levels, thereby improving lung compliance and oxygenation.

How is surfactant therapy administered?

Surfactant therapy is typically administered via endotracheal tube installation or minimally invasive techniques such as Less Invasive Surfactant Administration (LISA). The surfactant is delivered directly into the infant’s lungs, either manually or using specialised devices, under careful monitoring by healthcare professionals.

What are the side effects of surfactant therapy?

Common side effects of surfactant therapy may include transient bradycardia, oxygen desaturation, airway obstruction, and pulmonary haemorrhage. However, these side effects are usually mild and transient, and most infants tolerate surfactant therapy well.

How do you administer surfactant to a baby?

Surfactant is administered to a baby either through an endotracheal tube, instilled directly into the lungs or via minimally invasive techniques such as LISA, delivered into the pharynx and subsequently distributed into the lungs.

What is the first-line therapy for RDS?

Surfactant therapy is considered the first-line therapy for Respiratory Distress Syndrome in premature infants. It is aimed at addressing surfactant deficiency and improving lung function to alleviate respiratory distress and prevent complications.

How late can you give surfactant?

Surfactant therapy can be administered at any time after birth if the infant meets the criteria for treatment, regardless of the duration of respiratory distress. However, early initiation of surfactant therapy is recommended to maximise its efficacy and minimise the risk of complications.

How long does RDS last?

The duration of Respiratory Distress Syndrome varies depending on factors such as gestational age, severity of lung immaturity, and response to treatment. With appropriate management, including surfactant therapy and supportive care, most infants with RDS show improvement within a few days to weeks after birth.

What are the benefits of surfactant therapy?

Surfactant therapy offers numerous benefits for premature infants with RDS, including improved oxygenation, reduced need for mechanical ventilation, decreased risk of complications such as bronchopulmonary dysplasia and intraventricular haemorrhage, and improved long-term neurodevelopmental outcomes. 

By restoring surfactant levels and enhancing lung function, surfactant therapy plays a crucial role in optimising the health and well-being of neonates battling RDS.